APTO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 16:00):

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States...

Stats
Today's Volume	25 039.00
Average Volume	75 077.00
Market Cap	19.33M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.820 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.0130 (1.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-05	Payne Fletcher	Buy	55 000	Employee Stock Option (Right to Buy)
2024-02-05	Bejar Rafael	Buy	35 000	Employee Stock Option (Right to Buy)
2024-02-05	Ledru Philippe	Buy	11 000	Employee Stock Option (Right to Buy)
2024-02-05	Rice William G.	Buy	70 000	Employee Stock Option (Right to Buy)
2024-02-05	Seizinger Bernd R.	Buy	3 333	Director Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 9 955 760 \| Sell: 550 471

Aptose Biosciences Inc Correlation

10 Most Positive Correlations
CFRX	0.958
FWRD	0.955
RMRM	0.954
AGRX	0.954
PACB	0.953
AKAN	0.951
BGFV	0.947
QNRX	0.947
EMBC	0.945
PETS	0.944

10 Most Negative Correlations
TBSA	-0.973
AGGR	-0.972
AEAC	-0.971
AVAC	-0.969
SCOB	-0.969
KAII	-0.969
CRZN	-0.968
JUGG	-0.968
LEGA	-0.968
MSAC	-0.967

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptose Biosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-474 545 (0.00 %)
EPS:	$-7.72

FY	2023
Revenue:	$0
Gross Profit:	$-474 545 (0.00 %)
EPS:	$-7.72

FY	2022
Revenue:	$0
Gross Profit:	$-507 079 (0.00 %)
EPS:	$-6.67

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Realtime updates for Aptose Biosciences Inc [APTO]

Upcoming Earnings Alert